AIM ImmunoTech Inc (NYSE:AIM) CEO Thomas Equels joined Proactive’s Stephen Gunnion after the company announced the start of an NCI-funded Phase 2 study of its product candidate Ampligen in melanoma.
Equels gave an overview of Ampligen and explained the process for the Phase 2 study and the steps AIM will take if it is successful.
He also provided an overview of the AIM’s other programs with Ampligen.
#ProactiveInvestors #AIMImmunoTech #Ampligen #NYSE
